Inclusion Criteria:  Healthy volunteers, men and women aged 18 to 45 years (inclusive); Provided written Informed Consent Form of a Healthy Volunteer for Participation in the Clinical Study before the beginning of any screening procedures; Ability (to the opinion of the investigator) to fulfill all requirements of the Study Protocol, i.e. the volunteer's ability for adequate collaboration; Body mass index is within the limits (> 18,5 kg/m2 and < 30,0 kg/m2); Persons free from any acute and chronic diseases of cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, and respiratory system; Results of physical, instrumental, and laboratory examination of volunteers are within the normal limits, or any deviations are classified by the investigator as clinically irrelevant; Chest fluorography or radiography results are within the normal limits (the examination should be carried out no earlier than 9 months before the screening moment), or any deviation is classified by the investigator as clinically irrelevant; Women and men have to use medically confirmed barrier method of contraception during the whole study period; Volunteers have to be non-smokers or smoke up to 10 cigarettes a day inclusive; Volunteers need to undertake to follow all general diet limitations during the whole study period.  Exclusion Criteria:  Subjects with evidence or suspicion of any relevant clinical abnormality (as based on medical history, physical examination, vital signs, chest X-ray, and 12-lead ECG) Known hypersensitivity to meloxicam and/or other investigational products ingredients; Compromised allergologic history; Subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs; Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months; Subjects with peripheral oedema; Any previously incurred diseases or surgical interventions which, to the investigator's opinion, may affect pharmacokinetics of the investigational product; Positive result of HIV, syphilis, hepatitis B and C markets test; Positive result of urine test for narcotic substances (amphetamine, metamphetamine, morphine, marijuana, cocaine); Positive result of alcohol vapors test in expired air; Pregnancy (positive result of urine pregnancy test in women) and lactation period; Incurred acute infectious diseases within 28 days before beginning of the study; Use of any medicinal products within 14 days before beginning of the study; Blood donation or blood loss of more than 300 ml in less than 30 days before beginning of the study; Participation in any other clinical study during the last 90 days before beginning of the study; Other reasons which, to the investigator's opinion, make the volunteer's participation in the study undesirable.